DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pernicious anemia — screening already-approved drugs against its 27-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePernicious anemia maps to a 27-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pernicious anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
GDP-mannose 4,6-dehydratase (GMDS) — GMDS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet napdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6GPK · 1.47 Å · ligand NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NAP). Experimental structure, not a prediction.
What the evidence adds up to
A 2016 case report describes a young woman with severe anaemia who was found to have both autoimmune haemolytic anaemia and pernicious anaemia. The authors state that the concurrence of these two haematological diagnoses in a single patient is rare. No sample size or survival data are given because this is a single case.
A 1921 study of transfused blood in pernicious anaemia patients found no evidence of a hemolytic toxin causing the anaemia. The authors argue that the periods of active blood destruction occasionally seen during transfusions are due to the activity of the body’s own blood-destroying organs, not to an intrinsic weakness of the pernicious anaemia red blood cell. They question whether blood destruction is as important a factor in producing the anaemia as was then assumed.
A 1992 review states that pernicious anaemia is confidently diagnosed when a patient has megaloblastic haematopoiesis, low serum cobalamin, and impaired vitamin B12 absorption that is corrected by intrinsic factor. It notes that neurologic disorders in pernicious anaemia patients are now less severe than in the past, highly responsive to therapy, and can occur without anaemia or macrocytosis. The review warns that a low serum cobalamin level in the absence of anaemia, especially with a neurologic disorder, should not be ignored.
What is still missing is any controlled trial data on treatment outcomes, any systematic comparison of therapies, and any prospective study that stratifies patients by the presence or absence of concurrent autoimmune haemolysis. The evidence base remains limited to case reports, old physiological studies, and narrative reviews.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Case Reports in Hematology · 2016 · 23 citations · open access
Pernicious Anemia with Autoimmune Hemolytic Anemia: A Case Report and Literature Review
AbstractPernicious anemia is a common cause of vitamin B12 deficiency. Here, we discuss a case of a young woman who presented with severe anemia along with a history of iron deficiency anemia. After a review of her clinical presentation and laboratory data, we identified an autoimmune hemolytic anemia and a concomitant pernicious anemia. The concurrence of both these hematological diagnoses in a patient is rare.
The Journal of Experimental Medicine · 1921 · 22 citations · open access
STUDY OF TRANSFUSED BLOOD
AbstractEvidence is presented to show that there is no hemolytic toxin producing the anemia in pernicious anemia. Partial evidence is presented to show that the periods of active blood destruction which are seen as the exception in pernicious anemia cases during a series of transfusions are due to the activity of the blood-destroying organs of the body rather than to the intrinsic weakness of the pernicious anemia blood corpuscle. It is questionable whether blood destruction is as important a factor in producing the anemia of pernicious anemia as it is at present usually assumed to be.
AbstractPernicious anemia can be confidently diagnosed in a patient who has megaloblastic hematopoiesis, low serum cobalamin level, and impaired vitamin B12 absorption correctable by administering intrinsic factor. Recent studies suggest that neurologic disorders in patients with pernicious anemia are less severe than in the past, highly responsive to therapy, and seen in the absence of anemia and macrocytosis. A low serum cobalamin level in the absence of anemia, particularly in a patient with a neurologic disorder, should not be ignored.
AbstractAbstract I have tried to review and clarify steps leading to our present knowledge of pernicious anemia as a clinical and etiologic entity. The early history is most illuminating. The development of the present concept of this complicated disease is a triumph of medical research. Many great names both in clinical and research fields are associated with the advance in knowledge of pernicious anemia. Further research will almost certainly clarify problems still unsolved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
